Ribomic Inc.

Tokyo Stock Exchange 4591.T

Ribomic Inc. EBITDA Margin for the year ending March 31, 2024

Ribomic Inc. EBITDA Margin is NA for the year ending March 31, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Ribomic Inc. EBITDA Margin for the year ending March 31, 2023 was -2,708.12%, a -26.36% change year over year.
  • Ribomic Inc. EBITDA Margin for the year ending March 31, 2022 was -2,143.15%, a -62.35% change year over year.
  • Ribomic Inc. EBITDA Margin for the year ending March 31, 2021 was -1,320.10%, a -78.07% change year over year.
  • Ribomic Inc. EBITDA Margin for the year ending March 31, 2020 was -741.32%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
Tokyo Stock Exchange: 4591.T

Ribomic Inc.

CEO Mr. Yoshikazu Nakamura Ph.D.
IPO Date Sept. 25, 2014
Location Japan
Headquarters Shirokanedai Usui Building
Employees 24
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

StockViz Staff

February 2, 2025

Any question? Send us an email